David McNaughton was Pfizer’s oncology team leader in charge of four marcoms staff in what he described as a ‘cross-functional’ brand team.
He was tasked with raising awareness of its oncology portfolio, including breast cancer treatment Aromasin, colon cancer chemotherapy drug Campto and pipeline kidney cancer treatment Sutent, which is currently awaiting approval from NICE (PRWeek, 14 September).
McNaughton said: ‘A big part of my remit was comms, med ed and dissemination of data.’
Based at Pfizer’s commercial HQ in Walton Oaks, Surrey, McNaughton worked with Weber Shandwick and healthcare specialists Athena Medical PR and Reynolds-Mackenzie. Pfizer could not be reached for comment.
In his new role as director of STEM Marketing, McNaughton will provide a marcoms audit service for B2B organisations, from strategy through to execution.
‘It enables a marketing team to quantify what is working well and what isn’t. It is a way of measuring effectiveness and showing where the deficiencies are in the process. It will work anywhere,’ he said.